Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program
about
Anticoagulation in Heart Failure: a ReviewIn vitro hepatic trans-differentiation of human mesenchymal stem cells using sera from congestive/ischemic liver during cardiac failureBilirubin as a prognostic marker in patients with pulmonary arterial hypertension.Liver dysfunction assessed by model for end-stage liver disease excluding INR (MELD-XI) scoring system predicts adverse prognosis in heart failurePreoperative serum albumin levels predict 1-year postoperative survival of patients undergoing heart transplantation.Relation of preoperative serum albumin levels to survival in patients undergoing left ventricular assist device implantation.Beta-blockers Associated with a Mortality Benefit in Patients with Systolic Dysfunction and Elevated Serum Bilirubin.The prognostic value of plasma soluble ST2 in hospitalized Chinese patients with heart failure.Low health-related quality of life is a predictor of major adverse cardiovascular events in patients with chronic nonischemic heart failure.Five-year survival of patients with chronic systolic heart failure of ischemic and non-ischemic etiology: analysis of prognostic factors.Depression is the strongest predictor of long-term outcome in patients with chronic nonischemic heart failureLiver function parameters in hip fracture patients: relations to age, adipokines, comorbidities and outcomes.Plasma amino acid profiling identifies specific amino acid associations with cardiovascular function in patients with systolic heart failureDirect comparison of serial B-type natriuretic peptide and NT-proBNP levels for prediction of short- and long-term outcome in acute decompensated heart failure.Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study.Serum Bile Acids in Repaired Tetralogy of Fallot: A Marker for Liver and Heart?Liver abnormalities in cardiac diseases and heart failureLow Cardiac Output Leads Hepatic Fibrosis in Right Heart Failure Model Rats.Hepatic dysfunction and survival after orthotopic heart transplantation: application of the MELD scoring system for outcome prediction.Association of serum transaminases with short- and long-term outcomes in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary interventionModel for End-stage Liver Disease excluding INR (MELD-XI) score in critically ill patients: Easily available and of prognostic relevance.Anticoagulation in Heart Failure: a Review.Relation of circulating liver transaminase concentrations to risk of new-onset atrial fibrillation.Predictors of cardiac hepatopathy in patients with right heart failure.Liver function predicts survival in patients undergoing extracorporeal membrane oxygenation following cardiovascular surgery.Serum Bilirubin and 6-min Walk Distance as Prognostic Predictors for Inoperable Chronic Thromboembolic Pulmonary Hypertension: A Prospective Cohort Study.Serum bilirubin as a prognostic marker in patients with acute decompensated heart failureThe predictive value of transaminases at admission in patients hospitalized for heart failure: findings from the RO-AHFS registryNoncardiac comorbidities and acute heart failure patients.Hepatic dysfunction in ambulatory patients with heart failure: application of the MELD scoring system for outcome prediction.Liver disease in the patient with Fontan circulation.Impact of systemic venous congestion in heart failure.The cardiorenal syndrome in heart failure: cardiac? renal? syndrome?Cardiac surgery in patients with Gilbert's syndrome.Prevalence and importance of comorbidities in patients with heart failure.Anticoagulation in heart failure: current status and future direction.Co-morbidities in heart failure.Interactions of the heart and the liver.Cardiohepatic syndrome: liver injury in decompensated heart failure.Novel renal biomarkers to assess cardiorenal syndrome
P2860
Q28087068-CAF06B0D-19BF-41BB-ACDE-168440C096AFQ28541090-121392F7-D729-4D0C-9C94-5D57DA233A26Q33562258-BF2BD96A-81CB-4B1A-BB22-608B974317D0Q33793631-C6957C61-5DA4-48C1-B7F1-0F41CDEDBD19Q33818484-278D8421-E812-45AA-92B5-7EEA8869869DQ33818507-4D8594DC-69A3-48DD-9CA4-B026C7A11008Q34211025-7CBFE75F-454D-4618-8E68-9A96C631FA03Q34408467-450EFF39-8F99-4732-A533-131158B65583Q34821528-7BE42FFC-EBF5-4068-A910-65422ADD939EQ34821843-A8D6A1C1-5455-4C39-B8D2-8D6B434640B3Q34821932-F4EA9014-C17E-4B9C-93AF-980F3C65BE0EQ34942815-C4040581-5A74-4103-94D0-79DF90A89991Q35058430-C7A22639-1DD3-43E6-AE21-D68626261F02Q35567128-295D6172-4E37-4D43-8565-04F8A17BD545Q35684817-A22E061D-D65B-4E63-BB4D-4C425D338447Q35867362-40B99F28-8A90-4D6B-82B5-96846641A256Q35902564-38E14BB5-14B1-4346-A4A5-0F9B921C929AQ35919808-4E9253DA-3883-44A4-BB78-0E1125F2F201Q35980846-5E3FD915-2C2C-40C3-B90D-DDAB5BEC1445Q36262814-2672DB5B-1268-4320-80FE-66CE5EAF76FDQ36267363-85643900-3C17-42F3-B947-D09C69FBBBD6Q36381170-C3B41F8D-064F-4B94-93D3-4A85E8126890Q36514049-EA875CAF-5420-43AC-94C0-207D5AB37ABBQ36516184-3EE31756-4062-4AEC-A99A-8D98DD9A1DC0Q36679145-BDC1C2DC-592F-4925-BC98-CC39AE3B039DQ36694640-D60E5338-1F4C-473B-A3D0-F796C4F50A5EQ36844380-D8B3610B-0340-40E8-9988-971C071FDC75Q37291800-70AC9ADE-B646-44C0-B59B-3685FEDEE5B1Q37531314-D5FC4E22-B17A-4008-A059-FC7F82A14806Q37612329-0145FE60-62C8-4C07-B9C8-76204CF5A06FQ37858605-ABEAB719-9698-46C6-BD0F-A9D591ABFE3EQ37921161-2D76DD21-36BC-40F4-B5E3-90CEE0C2708EQ37956552-4CEADBB2-CC7F-458A-903A-70B9380668B4Q37965849-C896CADD-7E47-4E08-8ECE-5D62649E333DQ38037383-4E4DF425-859A-4E05-9BF2-C8095DC61013Q38044305-9D9F6049-0957-4964-82A6-A2081D815A1FQ38069787-21EB3DA3-A312-455E-A329-414DE133F26FQ38121525-905E4B87-A831-4DD5-A036-38395B4B3489Q38217113-504F196F-2FC7-44F1-8CCB-3F45BB5042FFQ38252731-CB34AD18-A154-42BD-A1AD-858EEE7966AA
P2860
Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Liver function abnormalities a ...... and Morbidity (CHARM) program
@ast
Liver function abnormalities a ...... and Morbidity (CHARM) program
@en
type
label
Liver function abnormalities a ...... and Morbidity (CHARM) program
@ast
Liver function abnormalities a ...... and Morbidity (CHARM) program
@en
prefLabel
Liver function abnormalities a ...... and Morbidity (CHARM) program
@ast
Liver function abnormalities a ...... and Morbidity (CHARM) program
@en
P2093
P2860
P50
P356
P1476
Liver function abnormalities a ...... and Morbidity (CHARM) program
@en
P2093
CHARM Investigators
Duolao Wang
Eric L Michelson
G Michael Felker
John J V McMurray
Larry A Allen
Marc A Pfeffer
Stuart Pocock
P2860
P304
P356
10.1093/EURJHF/HFN031
P577
2009-02-01T00:00:00Z